Selecting the Right CRO for a Phase 2 Orphan Disease CNS Study
Summary
A privately owned, early-stage biotech focused on CNS therapies was preparing for a Phase 2 orphan disease study.
With study start-up approaching, the sponsor needed to identify a CRO that could meet the specific needs of the trial and establish the right operational and commercial model for the partnership.
The selection process also needed to be rigorous and fully documented. The sponsor wanted a clear record of how potential CROs had been assessed and why the final decision had been made, giving internal stakeholders and the Board confidence in the selection.
We designed and co-ordinated the process from the initial RFI through RFP, bid defense, and contracting. We assessed different partnership models, managed CRO communications, documented decision-making, and supported negotiations across the SUA, MSA, and Work Order.
The sponsor selected its CRO within four months and achieved first patient in according to the planned study timeline.
What Seuss+ Delivered
A Structured CRO Selection and Contracting Process We designed and managed a CRO selection process around the specific needs of the sponsor and its Phase 2 orphan disease CNS study.
The work began with a structured RFI to assess potential CRO partners before moving into the RFP and bid defense stages. We co-ordinated the evaluation process, giving the sponsor a consistent way to compare potential partners and the information needed to make a well-supported decision.
We also assessed different partnership models to identify the model best suited to the study and the sponsor’s needs.
Throughout the process, we managed communications with the CROs and documented the evaluation and decision-making, creating a clear record of how the selected CRO was appointed.
Once the CRO had been selected, we supported negotiations across the SUA, MSA, and Work Order, including payment terms and KPIs designed to strengthen CRO accountability during study delivery.
The Risk/Challenge
The sponsor was preparing for a Phase 2 orphan disease CNS study and needed to identify the right CRO partner
As a small, early-stage biotech, the sponsor needed a structured selection process without slowing study start-up
Potential CROs and partnership models needed to be assessed consistently
The sponsor needed clear documentation behind the final selection decision
Internal stakeholders and the Board needed confidence in how the CRO had been selected
CRO communications, evaluations, and decision-making needed to be recorded throughout the process
Contract negotiations needed to support clear expectations and CRO accountability
Selection and contracting activities needed to progress without disrupting the planned study timeline
The Results
The sponsor selected its CRO within four months
First patient in was achieved according to the planned study timeline
Different partnership models were evaluated before the model best suited to the study was selected
The sponsor gained a consistent, data-led basis for comparing potential CRO partners
Internal stakeholders were aligned around the final CRO selection
The sponsor and its Board had a clear record supporting how and why the CRO had been selected
The CRO evaluation and selection process was fully documented to support audit and inspection readiness
Sponsor-friendly contractual terms were negotiated across the SUA, MSA, and Work Order
Payment terms and KPIs were established to support CRO accountability during study delivery
How We Helped
Designed a structured RFI process to assess potential CRO partners
Co-ordinated the end-to-end CRO selection process
Developed and managed the RFP
Co-ordinated the bid defense process
Created a consistent framework for comparing potential CRO partners
Evaluated different partnership models with the sponsor
Managed communications with participating CROs throughout the selection
Documented evaluations and decision-making to create a clear audit trail
Supported internal stakeholder alignment around the final CRO selection
Supported negotiations following CRO appointment
Negotiated the SUA, MSA, and Work Order
Helped establish payment terms and KPIs to support CRO accountability
Kept selection and contracting activities aligned with the wider study timeline
Frequently Asked Questions
Choosing a CRO can have a direct impact on study timelines, costs, and operational delivery. A structured process gives the sponsor a consistent way to assess potential partners against the specific needs of the study, rather than relying on reputation, existing relationships, or headline proposals. It also creates a clear record of why the final decision was made.
Yes. We can support the process from the initial RFI and RFP through CRO evaluation, bid defense, decision-making, and contract negotiation. This gives the sponsor continuity throughout the selection process while allowing the internal team to stay focused on the wider clinical development program.
CRO selection and contracting need to be planned alongside the wider study timeline. In this case, we co-ordinated the RFI, RFP, bid defense, decision-making, and contracting activities so the sponsor could select its CRO within four months and achieve first patient in according to plan.
Other Related Case Studies
Schedule a consultation now
Key Takeaways
- A privately owned, early-stage biotech preparing a Phase 2 orphan disease CNS study needed the right CRO before study start-up, with a fully documented decision its Board could stand behind.
- Seuss+ ran the full process from RFI through RFP, bid defense, and contracting, managing every CRO communication and evaluating different partnership models along the way.
- The sponsor selected its CRO within four months and achieved first patient in according to the planned study timeline.
- Sponsor-friendly terms were negotiated across the SUA, MSA, and Work Order, including payment terms and KPIs that tie CRO performance to study delivery.
- Every evaluation and decision was documented, giving the Board a clear record of why the CRO was chosen and supporting audit and inspection readiness.
Choosing a CRO is one of the biggest decisions an early-stage biotech makes, and it almost always happens under time pressure. A structured process does not slow you down. It is what lets you move quickly and still show your Board exactly why you chose the partner you did.
Choosing a CRO for your next study?
Book a 30-minute call. We will walk through how a structured RFI, RFP, and bid defense process would work for your trial and your timeline.
Book an intro call
